Background Vasopressor-induced hypertension is routinely indicated for prevention and treatment of cerebral vasospasm (CVS) after subarachnoid haemorrhage (SAH). Mechanisms underlying patients' clinical improvement during vasopressor-induced hypertension remain incompletely understood. The aim of this study was to evaluate angiographic effects of normovolaemic Norepinephrine (NE)-induced hypertension therapy on the rabbit basilar artery (BA) after SAH. Methods Cerebral vasospasm was induced using the onehaemorrhage rabbit model; sham-operated animals served as controls. Five days later the animals underwent follow-up angiography prior to and during NE-induced hypertension.
Introduction
Delayed cerebral vasospasm (CVS) is considered the principal cause of high morbidity and mortality in patients undergoing treatment of subarachnoid haemorrhage [27] , leading to delayed ischaemic neurological deficits (DIND), permanent neurological damage and death. It mainly transiently occurs 4-8 days after onset of SAH [5, 9, 14, 24] . Despite decades of research, the pathogenesis of CVS remains unclear [22] .
Progress has been made in the management of CVS. Routine protocols combine early surgery with systemic administration of the calcium channel antagonist, nimodipine, and hyperdynamic therapy. As a result, the mortality and morbidity due to CVS have been reduced to 5-10%, compared to about 20% rates in the early 1980s [24] .
Hyperdynamic therapy consists of haemodilution, hypervolaemia and induced hypertension (HHH), and is routinely administered despite some controversy [12, 14, 19, 24, 28] . The efficacy of haemodilution and hypervolaemia in particular has been seriously questioned lately [13, 17, 23, 24] . A relative risk of extracranial complications has been reported, and includes pulmonary oedema, hyponatraemia and congestive heart failure, to mention the most common. Induced hypertension, although associated with the possible risk of rebleeding from the aneurysm, has been evaluated as being safe [6, 16] . Vasopressors such as norepinephrine (NE) and phenylephrine are most commonly used clinically to induce hypertension during HHH therapy after SAH [14] . An improvement in patients' cerebral blood flow (CBF) and, thus, cerebral perfusion and clinical outcome has been documented in several studies [1, 8, 10, 17, 18, 23] . However, the mechanism underlying patients' enhanced clinical status remains incompletely understood. The aim of this study was to evaluate angiographic effects of normovolaemic NE-induced hypertension therapy on the rabbit BA after SAH.
Materials and methods

Study design
The protocol of this study was reviewed and approved by the Swiss Institutional Animal Care and Use Committee as meeting the Swiss guidelines for laboratory animal use (approval #16/06). Twenty-four adult New Zealand White rabbits of either sex weighing 2.6-3.6 kg were randomly assigned to two experimental groups (12 animals each). One of these groups underwent experimental SAH on day 0, while the other served as a sham-operated control. All surgical procedures were performed under sterile conditions.
Angiography
After induction of general anaesthesia by intramuscular administration of ketamine (30 mg/kg) and xylazine (6 mg/kg), digital subtraction angiography (DSA) was performed on day 0 prior to SAH and on day 5 post SAH and sham-operation, respectively, in accordance with our protocol recently reported [15] . In brief, the rabbits' left (day 0) or right (day 5) subclavian artery was microsurgically cannulated using a catheter that was fixed distal to the vertebral branch. Subsequently, images of the vertebro-basilar system were obtained by rapid sequential DSA using intra-arterial bolus injection of non-ionic iopamidol (0.6 ml/kg) as contrast agent. Meanwhile, the arterial blood gas status was analysed to monitor ventilation parameters. The average diameter of the BA was digitally 
Cerebral vasospasm model
Following baseline DSA on day 0, the rabbits underwent the one-haemorrhage SAH rabbit model, as reported earlier by our group [4, 15] . Briefly, after draining of 1.0 ml cerebrospinal fluid, an equal amount of unheparinised autologous arterial blood was injected into the cerebro-medullary cistern under microscopic view to imitate SAH in order to induce CVS. An equal amount of isotonic saline solution was used instead in controls. Postsurgical pain relief was managed by subcutaneous administration of buprenorphine (0.1-0.2 mg/kg) for up to 36 h after SAH.
Induction of hypertension
After performance of pre-treatment follow-up DSA on day 5, peripheral hypertension was induced by continuous central arterial administration of NE (2.3-4.0μg * min * −1 kg −1 ) in dose-dependency to monitored blood pressure, the mean arterial pressure (MAP) in particular. Under constant conditions, a second follow-up DSA was performed to register any change of the BA diameter during peripheral hypertension.
Drugs
The following drugs were used: buprenorphinum (Temgesic® 0.3 mg/ml, Essex Chemie, Lucerne, Switzerland); iopamidol (Iopamiro® 300 mg/ml, Bracco, Milano, Italy); isoflurane (Forene® 99%, Abbott Laboratories, Abbott Park, IL, USA); ketamine HCl (Ketalar® 50 mg/ml, Pfizer AG, Zurich, Switzerland); norepinephrine (Noradrenalin Bichsel®, Bichsel, Interlaken, Switzerland); sodium thiopental (Pentothal® 25 mg/ml, Abbott Laboratories, Abbott Park, IL, USA); and xylazine HCl (Xylapan® 20 mg/ml, Vetoquinol AG, Bern, Switzerland).
Statistical methods
Values were expressed as a mean in each group ± SEM (n = number of animals). Statistical significance between 2 means and multiple means was determined by parametric One-way-ANOVA and Bonferroni's multiple comparisons post-testing, respectively. Statistical significance was con- sidered if the P-value was less than 0.05 (p<0.05) in context of the 95% confidence intervals of the difference examined (95% CI of diff).
Results
Arteriographic changes of the vessel diameter
On day 5 after SAH the diameter of the BA was significantly narrowed by 14.2±2.8%, to 640.5±17.5µm in pre-treatment state compared to the baseline angiogram (746.2±20.5µm) on day 0 (n=12, p<0.01, 95% CI of diff: 37.4-175.0µm). In contrast, the BA diameter in controls was on average 740.6± 10.4µm wide on the baseline angiogram on day 0 and remained statistically unchanged to the pre-treatment state on day 5 (716.8 ± 15.5 µm) (n = 12, p > 0.05, 95% CI of diff: −34.7µm to 82.3µm). The SAH and control groups were, thus, significantly different from each other in diameter five days after the induction of SAH and the sham operation, respectively, prior to the administration of NE (p<0.05, 95% CI of diff: 10.0-143.5µm) (Fig. 1) . Continuous administration of NE on day 5 in the SAH group caused significant arteriographic dilation of the spastic vessel by 12.97% to 722.5±23.7µm in diameter (n=12, p<0.05, 95% CI of diff: 13.8-150.2µm). In controls, the administered NE significantly dilated the BA by 8.86%, to 779.9±24.1µm in relation to 716.8±15.5µm in the pretreatment state (n = 12, p < 0.05, 95% CI of diff: 4.6-121.6µm). During continuous administration of NE on day 5, the groups did not statistically differ in BA diameter (p>0.05, 95% CI of diff: −9.4µm to124.1µm) (Fig. 1) . The relative dilating effect on the BA diameter in the SAH group (+12.97±2.52%) was also statistically insignificant in comparison to the relative effect of NE-induced hypertension detected in the BA of controls (+8.86±2.66%, n=12, p> 0.05, 95% CI of diff: −3.67 to 11.8) ( Table 1) .
The initial blood gas parameters, such as pO 2 (54.8 ± 1.7 mmHg), pCO 2 (51.9± 1.2 mmHg) and pH (7.38±0.01), did not change compared to the values monitored during follow-up angiography on day 5 in both the SAH (p>0.05) and control groups (p>0.05), and did not statistically differ between the two groups (p>0.05).
Assessed changes of arterial blood pressure
During the baseline angiography on day 0, the MAP of the SAH group was at a level of 73.7±2.1 mmHg (n=12). It remained statistically unchanged in comparison to its MAP pre-treatment assessment 5 days later (70.0±1.9 mmHg, p> 0.05, 95% CI of diff: −3.2 to 10.5 mmHg). Correspondingly, controls showed similar MAP values. They started at a level of 73.9±2.8 mmHg at baseline on day 0 and remained statistically unchanged at 72.0±3.1 mmHg in pre-treatment state on day 5 (n=12, p>0.05, 95% CI of diff: −6.4 mmHg to 10.3 mmHg). In SAH animals, continuous administration of NE on day 5 induced a highly significant increase in MAP to 136.0±2.1 mmHg (n=12, p<0.001, 95% CI of diff: 59.2-72.9 mmHg) compared to their pre-treatment state. Corresponding constant hypertension at a MAP level of 137.8±1.3 mmHg was achieved in controls (n=12); it also showed a highly significant MAP rise compared to the time prior to the administration of NE on day 5 (p<0.001, 95% CI of diff: 57.5-74.1 mmHg) (Fig. 2) .
The MAP level of the SAH group was similar to the level in controls throughout the pre-NE state within the 5 days the experiment lasted (p>0.05). There was also no significant difference detected in the extent of induced hypertension between those two groups (n=12 each, p> 0.05, 95% CI of diff: −6.2 mmHg to 9.7 mmHg) ( Table 1 ).
Discussion
Since it was first described in the 1970s, several studies have focused on the efficacy of vasopressor-induced hypertension therapy after SAH. The potency in both Fig. 3 The Hagen-Poiseuille law of laminar flow is extrapolated to CBF and put in context to our results prevention and treatment of CVS has been examined. The efficacy of the therapy as a preventive approach remains controversial due to conflicting data reported. While some authors observed in non-controlled, non-randomised trials that induced hypertension as part of HHH was beneficial in preventing CVS and DIND [20, 26, 29] , Egge et al. was not able to repeat these finding in his prospective, controlled and randomised setting [3] . The preventive efficacy is thus considered questionable, with the need of induced hypertension therapy having been examined separately in a large, randomised, controlled clinical trial [14, 28] .
However, vasopressor-induced hypertension is used routinely in the clinic and is-in contrast to the preventive approach-recommended for the treatment of clinical or angiographic CVS which is resistant to nimodipine [14, 24] . Support is based on several studies: three of them included additional hyperdynamic targets as part of HHH and concluded that there were benefits in the treatment of CVS in terms of enhancing CBF or improving clinical outcome [1, 8, 18] . Another five studies examined induced hypertension therapy separately from the haemodilutional and hypervolaemic approach and came to similar conclusions regarding its efficacy in terms of cerebral perfusion or neurological deficits (Table 2) [2, 7, 17, 21, 23] . In fact, hypertension has been demonstrated to be superior to hypervolaemia in its effectiveness [7, 17, 23] . Due to the lack of large, blinded, randomised and controlled trials on its efficacy in treating CVS, however, its scientific level of evidence has not exceeded level II.
The causes underlying the clinical observation of enhanced CBF and improved clinical outcome by vasopressor-induced hypertension in patients suffering from CVS have remained uncertain. During CVS the main cerebral vasculature resistance is shifted from the small arterioles to the narrowed major cerebral vessels. The vascular capacity of auto-regulation is impaired in the cerebral branches supplied by the narrowed arteries [11, 25] . CBF through the narrowed vessels thus becomes the limiting factor for the cerebral perfusion. Based on the Hagen-Poiseuille law of laminar flow, CBF may be manipulated by blood pressure gradient, vessel diameter and blood viscosity. So far, the enhanced CBF observed as a result of induced hypertension has been suggested to be dependent on the increase in blood pressure gradient alone [18, 21, 24] . Our data, however, demonstrate a significant dilatation of the narrowed vessels during NE-induced hypertension in an experimental SAH model. Therefore, we suggest that the clinical effect observed is additionally dependent on the dilating effect on the spastic vessel (Fig. 3) . The significant increase in vessel diameter, along with the significant increase in blood pressure gradient, may, thus, cause the enhanced CBF and improved clinical outcome observed in the clinical studies during vasopressor-induced hypertension. The mechanism itself of the dilatory effect of NE-induced hypertension on the vessel diameter remains unclear and is subject to further investigation. Hypothetically, a haemodynamic effect might be possible as consequence of direct adrenergic effects on the cerebral vasculature. The pathophysiology of CVS, however, is likely to play a minor role in the dilatory effect observed in our study. The relative dilatory effect of NEinduced hypertension on the BA in SAH animals was merely insignificantly greater than in controls.
Finally, some limitations of this study have to be mentioned. Firstly, the study is limited in providing data about a possible linear relation between blood pressure increase and vasodilatation effect due to single point assessment at high MAP values. Thus, our results are limited in serving for extrapolation to low and very moderate states of induced hypertension. Secondly, our study does not provide data evaluating the consistency over the time of the vasodilatation effects observed; this aspect is subject to further investigation.
Conclusion
This study demonstrates that NE-induced hypertension therapy significantly dilates the vasospastic basilar artery in a SAH rabbit model. This angiographic finding may possibly serve as an additional explanation for the enhanced CBF and improved clinical outcome observed during vasopressorinduced hypertension therapy in patients suffering from CVS.
